CL2014003484A1 - Uso de nalmefeno en la reduccion del consumo de alcohol en un paciente con dependencia del alcohol; composicion farmaceutica oral; combinacion farmaceutica. - Google Patents

Uso de nalmefeno en la reduccion del consumo de alcohol en un paciente con dependencia del alcohol; composicion farmaceutica oral; combinacion farmaceutica.

Info

Publication number
CL2014003484A1
CL2014003484A1 CL2014003484A CL2014003484A CL2014003484A1 CL 2014003484 A1 CL2014003484 A1 CL 2014003484A1 CL 2014003484 A CL2014003484 A CL 2014003484A CL 2014003484 A CL2014003484 A CL 2014003484A CL 2014003484 A1 CL2014003484 A1 CL 2014003484A1
Authority
CL
Chile
Prior art keywords
nalmefene
patient
alcohol
pharmaceutical composition
reducing
Prior art date
Application number
CL2014003484A
Other languages
English (en)
Inventor
Lars Torup
Afsaneh Abbariki
Anna Bladström
Christine Persson
Didier Meulien
Per Sorensen
Thomas Jon Jensen
Jette Buch Ostergaar
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48703496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003484(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CL2014003484A1 publication Critical patent/CL2014003484A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2014003484A 2012-06-27 2014-12-22 Uso de nalmefeno en la reduccion del consumo de alcohol en un paciente con dependencia del alcohol; composicion farmaceutica oral; combinacion farmaceutica. CL2014003484A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261664804P 2012-06-27 2012-06-27
US201261721539P 2012-11-02 2012-11-02
US201261736740P 2012-12-13 2012-12-13
US201361788810P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2014003484A1 true CL2014003484A1 (es) 2015-02-27

Family

ID=48703496

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003484A CL2014003484A1 (es) 2012-06-27 2014-12-22 Uso de nalmefeno en la reduccion del consumo de alcohol en un paciente con dependencia del alcohol; composicion farmaceutica oral; combinacion farmaceutica.

Country Status (35)

Country Link
US (4) US20140005217A1 (es)
EP (4) EP3138564B1 (es)
JP (3) JP6258933B2 (es)
KR (1) KR20150023396A (es)
CN (1) CN104411313A (es)
AU (1) AU2013283281B2 (es)
BR (1) BR112014032555A2 (es)
CA (1) CA2874703C (es)
CL (1) CL2014003484A1 (es)
CO (1) CO7160087A2 (es)
CY (3) CY1118579T1 (es)
DK (3) DK2866808T3 (es)
EA (1) EA029908B1 (es)
ES (3) ES2609122T3 (es)
FI (1) FI3345604T3 (es)
HK (2) HK1208185A1 (es)
HR (3) HRP20230762T8 (es)
HU (3) HUE063313T2 (es)
IL (1) IL236035B (es)
LT (3) LT2866808T (es)
ME (2) ME02587B (es)
MX (1) MX371373B (es)
MY (1) MY166914A (es)
NZ (1) NZ702191A (es)
PH (1) PH12014502798A1 (es)
PL (3) PL2866808T3 (es)
PT (3) PT3345604T (es)
RS (2) RS55456B1 (es)
RU (1) RU2665373C2 (es)
SG (1) SG11201408704WA (es)
SI (3) SI2866808T1 (es)
SM (1) SMT201600471B (es)
UA (1) UA114199C2 (es)
WO (1) WO2014001427A1 (es)
ZA (1) ZA201409525B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
JP6419780B2 (ja) * 2013-04-17 2018-11-07 ハー・ルンドベック・アクチエゼルスカベット 睡眠障害患者の治療のためのナルメフェン
AU2015250611A1 (en) 2014-04-22 2016-11-24 H. Lundbeck A/S Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
US20170071590A1 (en) * 2015-09-10 2017-03-16 Suture Armor Llc Suture anchor
KR20190122431A (ko) 2018-04-20 2019-10-30 삼성전자주식회사 반도체 메모리 소자

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3814768A (en) 1971-11-26 1974-06-04 Lewenstein E 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
RU2004107501A (ru) * 2001-08-14 2005-02-20 Байотай Терапис Корпорейшн (Fi) Способ лечения алкоголизма или злоупотребления алкоголем
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
MA33368B1 (fr) 2009-05-25 2012-06-01 Lundbeck & Co As H Préparation de chlorhydrate de nalmefene à partir de naltrexone
AP3415A (en) 2010-11-05 2015-09-30 Lundbeck & Co As H Method for manufacturing of naltrexone
TR201803744T4 (tr) 2011-03-31 2018-07-23 Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi Skleroderma tedavisinde kullanım için naltrekson içeren bileşimler.
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations

Also Published As

Publication number Publication date
CY1126140T1 (el) 2023-11-15
PT3138564T (pt) 2018-04-03
AU2013283281A1 (en) 2014-12-11
EP4223296A3 (en) 2023-09-27
US9642849B2 (en) 2017-05-09
HRP20180363T1 (hr) 2018-04-20
CA2874703C (en) 2022-08-23
CA2874703A1 (en) 2014-01-03
US20140005217A1 (en) 2014-01-02
US20180028526A1 (en) 2018-02-01
RU2014151156A (ru) 2016-08-20
SI3138564T1 (en) 2018-04-30
DK3138564T3 (en) 2018-03-26
AU2013283281B2 (en) 2017-04-20
US20140005216A1 (en) 2014-01-02
WO2014001427A1 (en) 2014-01-03
EP3138564A1 (en) 2017-03-08
PH12014502798A1 (en) 2015-02-09
US20160375007A1 (en) 2016-12-29
RU2665373C2 (ru) 2018-08-29
SI2866808T1 (sl) 2017-01-31
MX2014015488A (es) 2015-03-06
MX371373B (es) 2020-01-28
SI3345604T1 (sl) 2023-08-31
EP2866808B1 (en) 2016-11-02
JP2019163275A (ja) 2019-09-26
PL3138564T3 (pl) 2018-06-29
SG11201408704WA (en) 2015-01-29
DK2866808T3 (en) 2017-01-16
HUE063313T2 (hu) 2024-01-28
EA201492152A1 (ru) 2015-11-30
PT3345604T (pt) 2023-07-17
ME03030B (me) 2018-10-20
ES2663532T3 (es) 2018-04-13
KR20150023396A (ko) 2015-03-05
BR112014032555A2 (pt) 2017-06-27
PT2866808T (pt) 2017-01-03
HK1208185A1 (en) 2016-02-26
EP3138564B1 (en) 2018-01-31
DK3345604T3 (da) 2023-07-24
ZA201409525B (en) 2016-08-31
NZ702191A (en) 2017-06-30
EP3345604B1 (en) 2023-06-07
FI3345604T3 (fi) 2023-07-28
CY1118579T1 (el) 2017-07-12
PL3345604T3 (pl) 2023-08-28
US10034874B2 (en) 2018-07-31
EP4223296A2 (en) 2023-08-09
EA029908B1 (ru) 2018-05-31
CY1120097T1 (el) 2018-12-12
HUE036272T2 (hu) 2018-06-28
ME02587B (me) 2017-06-20
ES2609122T3 (es) 2017-04-18
RS55456B1 (sr) 2017-04-28
CN104411313A (zh) 2015-03-11
RS57046B1 (sr) 2018-05-31
LT2866808T (lt) 2017-01-10
IL236035A0 (en) 2015-01-29
JP2018039810A (ja) 2018-03-15
HRP20230762T8 (hr) 2024-01-05
JP6857684B2 (ja) 2021-04-14
SMT201600471B (it) 2017-03-08
HRP20161717T1 (hr) 2017-02-10
HUE031110T2 (en) 2017-06-28
JP6258933B2 (ja) 2018-01-10
EP2866808A1 (en) 2015-05-06
LT3138564T (lt) 2018-04-10
PL2866808T3 (pl) 2017-04-28
IL236035B (en) 2018-12-31
MY166914A (en) 2018-07-24
EP3345604A1 (en) 2018-07-11
ES2950492T3 (es) 2023-10-10
JP2015521647A (ja) 2015-07-30
HRP20230762T1 (hr) 2023-10-13
HK1255683A1 (zh) 2019-08-23
LT3345604T (lt) 2023-08-10
CO7160087A2 (es) 2015-01-15
UA114199C2 (uk) 2017-05-10

Similar Documents

Publication Publication Date Title
IL269054A (en) A pharmaceutical preparation containing tesimaltone for use in the treatment of 24-NON
DK3222272T3 (da) Farmaceutisk sammensætning med carbetocin
HK1208801A1 (en) Orally administered medical composition
DK3181128T3 (da) Farmaceutisk nilotinib-sammensætning
BR112015000420A2 (pt) composto, composição farmacêutica, e, uso de um composto
IT1400982B1 (it) Collirio osmotico trans-epiteliale per la cura del cheratocono.
SMT201400069B (it) Formulazione farmaceutica
HK1206595A1 (en) Pharmaceutical compositions comprising benzyl alcohol
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BR112014020992A2 (pt) Composto,uso de composto na fabricação de um medicamento e composição farmacêutica
DK2815752T3 (da) Oral farmaceutisk sammensætning
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2014003484A1 (es) Uso de nalmefeno en la reduccion del consumo de alcohol en un paciente con dependencia del alcohol; composicion farmaceutica oral; combinacion farmaceutica.
HK1204992A1 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
HK1221423A1 (zh) 種中藥組合物
GB201511770D0 (en) Novel pharmaceutical formulationsand their use in the treatment of periodontal disease
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
HK1205698A1 (en) Chondroitin for use in medicine
BRPI0907700A2 (pt) Imidazopiridazinas como inibidores par1, produção das mesmas e uso como medicamentos
BR112014010432A2 (pt) uso médico
BR112013025604A2 (pt) uso de uma preparação na fabricação de uma composição nutricional líquida, composição nutricional líquida e uso da composição nutricional líquida
BR112013019283A2 (pt) composto, fármaco, composição farmacêutica e uso
EP2926811A4 (en) ARTEMISCULAR PHARMACEUTICAL COMPOSITION, MANUFACTURE AND USE
CL2014002203A1 (es) Uso de modafinilo en el tratamiento de sustitucion de cocainomanos; composicion farmaceutica oral que contiene modafinilo en la forma de su enantiomero dextrogiro.
BR112014000453A2 (pt) uso de uma composição de moldagem, e, garrafa de alimentação